FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / BMC Vet Res / Pharmacokinetics of dexmedetomidine in anaesthetized horses ...
BMC veterinary research2023; 19(1); 264; doi: 10.1186/s12917-023-03831-w

Pharmacokinetics of dexmedetomidine in anaesthetized horses following repeated subcutaneous administration and intravenous constant rate infusion.

Abstract: The inclusion of dexmedetomidine (DEX) within a balanced general anaesthesia protocol is effective in improving the clinical outcome and recovery quality of anaesthesia in horses. This study aimed to determine the pharmacokinetic profile of DEX following repeated subcutaneous (SC) administration at 2 µg/kg every 60 min till the end of the procedure in comparison to intravenous constant rate infusion (CRI) at 1 µg/kg/h in anaesthetized horses undergoing diagnostic procedures up to the end of the diagnostic procedure. Results: In the CRI and SC groups DEX maximum concentrations (Cmax) were 0.83 ± 0.27 ng/mL and 1.14 ± 0.71 ng/mL, respectively, reached at a time (Tmax) of 57.0 ± 13.4 min and 105.5 ± 29.9 min. Mean residence time to the last measurable concentration (MRTlast) was 11.7 ± 6.2 and 55.8 ± 19.7 min for the CRI group and SC groups, respectively. The apparent elimination half-life was 18.0 ± 10.0 min in the CRI group and 94.8 ± 69.8 min for the SC group, whereas the area under the curve (AUC0-last) resulted 67.7 ± 29.3 and 83.2 ± 60.5 min*ng/mL for CRI and SC group, respectively. Clearance was 16.26 ± 8.07 mL/min/kg for the CRI group. No signs of adverse effects were recorded in both groups. Conclusions: The pharmacokinetic profile of DEX following repeated SC administration in anaesthetized horses was comparable to intravenous CRI administration during the intranaesthetic period and beneficial during the recovery phase from general anaesthesia. The SC route could be considered as an alternative to CRI for improving the recovery quality of equine patients undergoing general anaesthesia.
© 2023. The Author(s).
Get Full Text
Publication Date: 2023-12-09 PubMed ID: 38071301PubMed Central: PMC10709979DOI: 10.1186/s12917-023-03831-wGoogle Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

This research study examined the effectiveness of the drug dexmedetomidine (DEX) administered subcutaneously (under the skin) and intravenously in anaesthetized horses undergoing diagnostics to improve their recovery from anesthesia. The pharmacokinetic profile of DEX was comparable for both administration methods, with no adverse effects noticed, suggesting that subcutaneous application could be considered as an alternative method.

Objectives of the Study

  • The main goal of this study was to determine the pharmacokinetic profile (how the drug is absorbed, distributed, metabolized, and excreted) of the drug DEX when administered subcutaneously and intravenously in anaesthetized horses.
  • The researchers wanted to compare the results from both methods, to see if the subcutaneous method could serve as an alternative to intravenous administration for improving the recovery quality of horses that have undergone general anesthesia.

Methods and Findings

  • DEX was administered to the horses via both methods: repeated subcutaneous administration at 2 µg/kg every 60 minutes, and intravenous constant-rate infusion at 1 µg/kg/hour.
  • The study monitored maximum concentrations of DEX and the time these concentrations were reached in the bloodstream for both groups.
  • The mean residence time of the drug (the average time the drug stays in the body) and the half-life (time taken for the drug’s concentration to decrease by half in the body) were also calculated for both groups.
  • The study found that the maximum concentrations and time to reach those concentrations were slightly higher for the subcutaneous group.
  • However, the mean residence time and elimination half-life were significantly higher in the subcutaneous group than in the intravenous group.

Conclusions and Potential Implications

  • The study concluded that the pharmacokinetic profile of DEX following repeated subcutaneous administration in anaesthetized horses was similar to intravenous infusion during the anaesthetic period and beneficial during the recovery phase.
  • Importantly, no adverse effects were recorded in either group, suggesting that DEX is safe to use in this context.
  • The results suggest that the subcutaneous route could be considered as a feasible alternative to intravenous infusion for improving the recovery quality of horses undergoing general anesthesia, potentially providing a more accessible and easy-to-apply method of administration.

Cite This Article

APA
Di Cesare F, Rabbogliatti V, Draghi S, Amari M, Brioschi FA, Villa R, Ravasio G, Cagnardi P. (2023). Pharmacokinetics of dexmedetomidine in anaesthetized horses following repeated subcutaneous administration and intravenous constant rate infusion. BMC Vet Res, 19(1), 264. https://doi.org/10.1186/s12917-023-03831-w

Publication

BMC veterinary research
ISSN: 1746-6148
NlmUniqueID: 101249759
Country: England
Language: English
Volume: 19
Issue: 1
Pages: 264

Researcher Affiliations

Di Cesare, Federica
  • Department of Veterinary Medicine and Animal Sciences, Università degli Studi di Milano, Milan, Italy.
Rabbogliatti, Vanessa
  • Department of Veterinary Medicine and Animal Sciences, Università degli Studi di Milano, Milan, Italy.
Draghi, Susanna
  • Department of Veterinary Medicine and Animal Sciences, Università degli Studi di Milano, Milan, Italy. susanna.draghi@unimi.it.
Amari, Martina
  • Department of Veterinary Medicine and Animal Sciences, Università degli Studi di Milano, Milan, Italy.
Brioschi, Federica Alessandra
  • Department of Veterinary Medicine and Animal Sciences, Università degli Studi di Milano, Milan, Italy.
Villa, Roberto
  • Department of Veterinary Medicine and Animal Sciences, Università degli Studi di Milano, Milan, Italy.
Ravasio, Giuliano
  • Department of Veterinary Medicine and Animal Sciences, Università degli Studi di Milano, Milan, Italy.
Cagnardi, Petra
  • Department of Veterinary Medicine and Animal Sciences, Università degli Studi di Milano, Milan, Italy.

MeSH Terms

  • Animals
  • Horses
  • Dexmedetomidine
  • Anesthesia, General / veterinary
  • Infusions, Intravenous / veterinary

Conflict of Interest Statement

The authors declare no competing interests.

References

This article includes 35 references
  1. Dugdale AHA, Taylor PM. Equine anaesthesia-associated mortality: where are we now?. Veterinary Anaesth Analg 2016;43(3):242–255.
    doi: 10.1111/vaa.12372pubmed: 26970940google scholar: lookup
  2. Johnston GM, Eastment JK, Wood J, Taylor PM. The confidential enquiry into perioperative equine fatalities (CEPEF): mortality results of phases 1 and 2. Vet Anaesth Analg 2002;29(4):159–170.
    doi: 10.1046/j.1467-2995.2002.00106.xpubmed: 28404360google scholar: lookup
  3. Valverde A. Balanced anesthesia and constant-rate infusions in horses. Veterinary Clin North Am Equine Pract 2013;29(1):89–122.
    doi: 10.1016/j.cveq.2012.11.004pubmed: 23498047google scholar: lookup
  4. Bettschart-Wolfensberger R, Larenza MP. Balanced anesthesia in the equine. Clin Techniques Equine Pract 2007;6(2):104–110.
    doi: 10.1053/j.ctep.2007.05.002google scholar: lookup
  5. Gozalo-Marcilla M, Gasthuys F, Schauvliege S. Partial intravenous anaesthesia in the horse: a review of intravenous agents used to supplement equine inhalation anaesthesia. Part 1: lidocaine and ketamine. Vet Anaesth Analg 2014;41(4):335–345.
    doi: 10.1111/vaa.12179pubmed: 24815750google scholar: lookup
  6. Gozalo-Marcilla M, Gasthuys F, Luna SPL, Schauvliege S. Is there a place for dexmedetomidine in equine anaesthesia and analgesia? A systematic review (2005–2017). J Vet Pharmacol Ther 2018;41(2):205–217.
    doi: 10.1111/jvp.12474pubmed: 29226340google scholar: lookup
  7. Leonardi F, Costa GL, Dubau M, Sabbioni A, Simonazzi B, Angelone M. Effects of intravenous romifidine, detomidine, detomidine combined with butorphanol, and xylazine on tear production in horses. Equine Veterinary Education 2020;32(S11):53–57.
    doi: 10.1111/eve.13040google scholar: lookup
  8. Gozalo-Marcilla M, Steblaj B, Schauvliege S, Duchateau L, Gasthuys F. Comparison of the influence of two different constant-rate infusions (dexmedetomidine versus morphine) on anaesthetic requirements, cardiopulmonary function and recovery quality in isoflurane anaesthetized horses. Res Vet Sci 2013;95(3):1186–1194.
    doi: 10.1016/j.rvsc.2013.09.014pubmed: 24148870google scholar: lookup
  9. Muller C, Hopster K, Hopster-Iversen C, Rohn K, Kastner SBR. Elaboration of a xylazine and dexmedetomidine infusion regime which provides a constant level of sedation in horses. Pferdeheilkunde 2012;28(6):668.
    doi: 10.21836/PEM20120605google scholar: lookup
  10. Guedes A, Knych H, Tucker L, Almeida DC, Baldo CF, Wendt-Hornickle E. Pharmacokinetics and clinical effects of xylazine and dexmedetomidine in horses recovering from isoflurane anesthesia. J Vet Pharmacol Ther 2020;43(4):369–376.
    doi: 10.1111/jvp.12855pubmed: 32166760google scholar: lookup
  11. Clark-Price SC. Recovery of horses from anesthesia. Veterinary Clin North Am Equine Pract 2013;29(1):223–242.
    doi: 10.1016/j.cveq.2012.11.001pubmed: 23498055google scholar: lookup
  12. Shane SE, Langston VC, Wills RW, Denney WS, Knych H, Fontenot RL. Pharmacokinetics and pharmacodynamics of intravenous continuous rate infusion and repeated intramuscular administration of dexmedetomidine in standing horses. J Vet Pharmacol Ther 2021;44(4):533–543.
    doi: 10.1111/jvp.12951pubmed: 33576078google scholar: lookup
  13. Bettembourg V, Dulgheriu D, Haga HA. Plasma concentrations at two dexmedetomidine constant rate infusions in isoflurane anaesthetized horses: a clinical study. Veterinary Anaesth Analg 2019;46(5):627–635.
    doi: 10.1016/j.vaa.2019.04.013pubmed: 31395482google scholar: lookup
  14. Sacks M, Ringer SK, Bischofberger AS, Berchtold SM, Bettschart-Wolfensberger R. Clinical comparison of dexmedetomidine and medetomidine for isoflurane balanced anaesthesia in horses. Vet Anaesth Analg 2017;44(5):1128–1138.
    doi: 10.1016/j.vaa.2016.12.061pubmed: 29037800google scholar: lookup
  15. Grimsrud KN, Ait-Oudhia S, Durbin-Johnson BP, Rocke DM, Mama KR, Rezende ML. Pharmacokinetic and pharmacodynamic analysis comparing diverse effects of detomidine, medetomidine, and dexmedetomidine in the horse: a population analysis. J Vet Pharmacol Ther 2015;38(1):24–34.
    doi: 10.1111/jvp.12139pmc: PMC4286451pubmed: 25073816google scholar: lookup
  16. Ranheim B, Risberg Å, Spadavecchia C, Landsem R, Haga HA. The pharmacokinetics of dexmedetomidine administered as a constant rate infusion in horses. J Vet Pharmacol Ther 2015;38(1):93–96.
    doi: 10.1111/jvp.12157pubmed: 25229603google scholar: lookup
  17. Rezende ML, Grimsrud KN, Stanley SD, Steffey EP, Mama KR. Pharmacokinetics and pharmacodynamics of intravenous dexmedetomidine in the horse. J Vet Pharmacol Ther 2015;38(1):15–23.
    doi: 10.1111/jvp.12138pubmed: 25066475google scholar: lookup
  18. Bettschart-Wolfensberger R, Freeman SL, Bowen IM, Aliabadi FS, Weller R, Huhtinen M. Cardiopulmonary effects and pharmacokinetics of i.v. dexmedetomidine in ponies. Equine Vet J 2005;37(1):60–64.
    doi: 10.2746/0425164054406801pubmed: 15651736google scholar: lookup
  19. Rabbogliatti V, Amari M, Brioschi FA, Di Cesare F, Zani DD, De Zani D. Use of dexmedetomidine repeated subcutaneous administration for balanced anaesthesia in horses. BMC Vet Res 2022;18(1):269.
    doi: 10.1186/s12917-022-03350-0pmc: PMC9275161pubmed: 35818051google scholar: lookup
  20. Doodnaught GM, Monteiro BP, Benito J, Edge D, Beaudry F, Pelligand L. Pharmacokinetic and pharmacodynamic modelling after subcutaneous, intravenous and buccal administration of a high-concentration formulation of buprenorphine in conscious cats. PLoS ONE 2017;12(4):e0176443.
    doi: 10.1371/journal.pone.0176443pmc: PMC5405979pubmed: 28445495google scholar: lookup
  21. Askar R, Fredriksson E, Manell E, Hedeland M, Bondesson U, Bate S. Bioavailability of subcutaneous and intramuscular administrated buprenorphine in New Zealand White rabbits. BMC Vet Res 2020;16(1):436.
    doi: 10.1186/s12917-020-02618-7pmc: PMC7656698pubmed: 33176781google scholar: lookup
  22. Askar R, Fredriksson E, Manell E, Hedeland M, Bondesson U, Bate S. Correction to: bioavailability of subcutaneous and intramuscular administrated buprenorphine in New Zealand White rabbits. BMC Vet Res 2021;17(1):169.
    doi: 10.1186/s12917-021-02858-1pmc: PMC8052722pubmed: 33863335google scholar: lookup
  23. Ingvast-Larsson C, Holgersson A, Bondesson U, Lagerstedt AS, Olsson K. Clinical pharmacology of Methadone in dogs. Vet Anaesth Analg 2010;37(1):48–56.
    doi: 10.1111/j.1467-2995.2009.00476.xpubmed: 20017819google scholar: lookup
  24. Chiavaccini L, Claude AK, Lee JH, Ross MK, Meyer RE, Langston VC. Pharmacokinetics and pharmacodynamics comparison between subcutaneous and intravenous butorphanol administration in horses. J Vet Pharmacol Ther 2015;38(4):365–374.
    doi: 10.1111/jvp.12191pubmed: 25484250google scholar: lookup
  25. Hanafi AL, Reed RA, Trenholme HN, Sakai DM, Ryan CA, Barletta M. Pharmacokinetics and pharmacodynamics of meperidine after intramuscular and subcutaneous administration in horses. Vet Surg 2021;50(2):410–417.
    doi: 10.1111/vsu.13545pubmed: 33242227google scholar: lookup
  26. Tobias JD. Subcutaneous dexmedetomidine infusions to treat or prevent drug withdrawal in infants and children. J Opioid Manag 2008;4(4):187–191.
    doi: 10.5055/jom.2008.0024pubmed: 18837201google scholar: lookup
  27. Uusalo P, Al-Ramahi D, Tilli I, Aantaa RA, Scheinin M, Saari TI. Subcutaneously administered dexmedetomidine is efficiently absorbed and is associated with attenuated cardiovascular effects in healthy volunteers. Eur J Clin Pharmacol 2018;74(8):1047–1054.
    doi: 10.1007/s00228-018-2461-1pubmed: 29666901google scholar: lookup
  28. Di Cesare F, Gioeni D, Ravasio G, Pellegrini A, Lucatello L, Bisutti V. Clinical pharmacokinetics of a dexmedetomidine-methadone combination in dogs undergoing routine anaesthesia after buccal or intramuscular administration. J Vet Pharmacol Ther 2019;42(4):392–400.
    doi: 10.1111/jvp.12771pubmed: 31197847google scholar: lookup
  29. Cagnardi P, Villa R, Ravasio G, Lucatello L, Di Cesare F, Capolongo F. Pharmacokinetics and sedative effects of dexmedetomidine in dairy calves. N Z Vet J 2017;65(1):14–18.
    doi: 10.1080/00480169.2016.1237313pubmed: 27643584google scholar: lookup
  30. European Commission. Commission decision 2002/657/EC, Aug 12, 2002, implementing council directive 96/23/EC concerning the performance of analytical methods and the interpretation of results. Official J Eur Communities 2002;L221:8–36.
  31. EMA. Studies to evaluate the metabolism and residue kinetics of veterinary drugs in food-producing animals: validation of analytical methods used in residue depletion studies. European Medicine Agency 2015.
  32. Yamaoka K, Nakagawa T, Uno T. Application of Akaike’s information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J Pharmacokinet Biopharm 1978;6(2):165–175.
    doi: 10.1007/BF01117450pubmed: 671222google scholar: lookup
  33. Risberg Å, Ranheim B, Krontveit RI, Lervik A, Haga HA. The cardiovascular status of isoflurane-anaesthetized horses with and without dexmedetomidine constant rate infusion evaluated at equivalent depths of anaesthesia. Vet Anaesth Analg 2016;43(4):412–423.
    doi: 10.1111/vaa.12315pubmed: 26488527google scholar: lookup
  34. Marcilla MG, Schauvliege S, Duchateau L, Gasthuys F. Cardiopulmonary effects of two constant rate infusions of dexmedetomidine in isoflurane anaesthetized ponies. Vet Anaesth Analg 2010;37(4):311–321.
    doi: 10.1111/j.1467-2995.2010.00537.xpubmed: 20636563google scholar: lookup
  35. Toutain PL, Bousquet-Melou A. Plasma clearance. J Vet Pharmacol Ther 2004;27(6):415–425.
    doi: 10.1111/j.1365-2885.2004.00605.xpubmed: 15601437google scholar: lookup
Subscribe to our newsletter
Join 99,357 horse owners like you who receive our email updates on horse health and nutrition.